First-in-Human trial tests engineered immune cells against tough ovarian cancer
NCT ID NCT07489287
Summary
This is a first-in-human study to test the safety and find the right dose of a new cell therapy called GB-5267 for women with ovarian cancer that has stopped responding to platinum chemotherapy. The therapy involves taking a patient's own immune cells (T-cells), engineering them in a lab to better target the cancer, and then infusing them back. The main goal is to see how much of the therapy the body can safely handle and to check for early signs that it might help fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.